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Abstract	
Bacterial	infections	of	the	central	nervous	system	are	a	neurological	emergency.	
Prompt	recognition	and	treatment	are	not	only	essential	to	prevent	mortality	but	also	to	
decrease	neurological	sequelae.	This	chapter	will	focus	on	the	two	most	common	central	
nervous	system	bacterial	infections,	bacterial	meningitis	and	spinal	epidural	abscess.	The	
eradication	of	the	pathogen	with	antimicrobial	therapy	is	the	easy	part.	It	is	the	recognition	
of	the	disorder,	the	understanding	of	the	diagnostic	studies	and	their	limitations,	and	the	
management	of	the	neurological	complications	that	requires	the	expertise	of	a	neurologist.	
Introduction	
There	are	a	number	of	bacterial	infections	of	the	central	nervous	system,	including	
meningitis,	brain	abscess,	cranial	and	spinal	epidural	abscess	and	subdural	empyema	and	
suppurative	dural	sinus	thrombophlebitis,	but	this	chapter	will	focus	on	the	two	central	
nervous	system	bacterial	infections	that	neurologists	encounter	the	most	often	and	have	a	
critical	role	in	diagnosis,	management	and	lifetime	care.	Those	infections	are	bacterial	
meningitis	and	spinal	epidural	abscess.		
Meningitis	
For	two	centuries,	the	clinical	presentation	of	bacterial	meningitis	was	recognized	as	the	classic	
triad	of	fever,	headache	and	stiff	neck.	Then	a	number	of	years	ago,	papers	began	to	appear	in	the	
literature	challenging	the	classic	triad,	primarily	over	the	lack	of,	or	ability	to	detect,	a	stiff	neck.	
This	controversy	was	resolved	by	the	recognition	that	the	majority	of	patients	with	bacterial	
meningitis	have	fever	(greater	than	or	equal	to	38.5°	C),	and	either	headache,	stiff	neck	or	an	
altered	level	of	consciousness.1‐3	A	symptom	that	is	often	present,	but	under	recognized	as	a	
symptom	of	central	nervous	system	(CNS)	infection,		is	vomiting.		
When	bacterial	meningitis	is	considered	a	possibility,	blood	cultures	should	be	obtained	and	
empiric	antimicrobial	and	adjunctive	therapy	initiated.	Empiric	antimicrobial	therapy	is	based	on	
predisposing	and	associated	conditions	which	predict	the	meningeal	pathogen.	Almost	all	
recommended	empiric	antimicrobial	regimens	include	a	third‐or	fourth	generation	cephalosporin	
plus	vancomycin.		Ampicillin	is	added	for	coverage	of	Listeria	monocytogenes	where	indicated	
(discussed	below),	and	metronidazole	when	the	predisposing	conditions	of	otitis,	sinusitis	or	
mastoiditis	are	present.4		Prior	to	or	with	the	first	dose	of	antibiotic	therapy,	dexamethasone	(0.15	
mg/kg	every	six	hours	for	2‐4	days)	is	initiated	in	patients	with	suspected	pneumococcal,	
meningococcal	or	Haemophilus	influenzae	type	b	meningitis.5‐7		Empiric	therapy	based	on	the	
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predicted	meningeal	pathogen	is	listed	in	Table	1	and	the	recommended	dose	of	antibiotic	is	listed	
in	Table	2.		
After	treatment	has	been	initiated,	thoughtful	consideration	of	etiological	organism,	diagnostic	
studies,	differential	diagnosis	and	treatment	can	be	undertaken	.		
Table 1 Empiric antimicrobial therapy based on the predicted meningeal pathogen 
Predisposing condition Bacterial pathogen Antibiotic 
Children and adults – 
community acquired 
Streptococcus pneumoniae 
and Neisseria meningitidis 
Third or fourth generation 
cephalosporin plus 
vancomycin 
Otitis, mastoiditis, sinusitis Streptococci spp., gram-
negative anaerobes 
(Bacteroides sp., 
Fusobacterium sp.), S. aureus, 
Haemophilus sp., 
Enterobacteriaceae 
Third or fourth generation 
cephalosporin plus 
vancomycin plus  
metronidazole
Adults over the age of 55 
and those with chronic illness 
Streptococcus pneumoniae, 
gram-negative bacilli, 
Neisseria meningitidis, Listeria 
monocytogenes, Haemophilus 
influenzae 
Third or fourth generation 
cephalosporin plus 
vancomycin plus ampiciilin 
Endocarditis viridans streptococci, S. 
aureus, Streptococcus bovis, 
HACEK group, Enterococci 
Third or fourth generation 
cephalosporin plus 
vancomycin 
Immunosuppressed Streptococcus pneumoniae, 
Listeria monocytogenes, 
Haemophilus influenzae 
Third or fourth generation 
cephalosporin plus 
vancomycin plus ampicillin 
Postneurosurgical Staphylococci, gram-negative 
bacilli 
Vancomycin plus meropenem 
or vancomycin plus 
ceftazidime 
Intraventricular device Staphylococci, gram-negative 
bacilli, anaerobes 
Vancomycin plus meropenem  
or vancomycin plus 
ceftazidime plus 
metronidazole 
The HACEK group is Haemophilus sp., Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, 
Eikenella corrodens,and Kingella kingae.  
Table 2. Recommended doses for the antibiotics commonly used in the treatment of bacterial 
central nervous system infections 
Antibiotic agent Total daily dosage (dosing interval in 
hours) 
Ampicillin Infants and children: 300 mg/kg/d (q6h) 
Adult: 12 g/d (q4-6h) 
Cefepime Infants and children: 150 mg/kg/d (q8h) 
Adult: 6 g/d (q8h) 
Cefotaxime Infants and children: 225-300 mg/kg/d (q6-8h) 
Adult: 8-12 g/d (q4-6h) 
Ceftriaxone Infants and children: 80-100 mg/kg/d (q12h) 
Adult: 4 g/d (q12h) 
Gentamicin Infants and children: 7.5 mg/kg/d (q8h) 
Adult: 5 mg/kg/d (q8h) 
Meropenem Infants and children: 120 mg/kg/d (q8h) 
Adult: 6 g/d (q8h) 
Metronidazole Infants and children: 30 mg/kg/d (q6h)  
Adult dose: 2000 mg/day (q6h) 
Nafcillin Infants and children: 200 mg/kg/d (q6h) 
Adult: 9-12 g/d (q4h) 
Penicillin G Infants and children: 0.3 mU/kg/d (q4-6h) 
Adult: 24 million units/d (q4-6h) 
Rifampin  Infants and children: 10-20 mg/kg/d (q12-24h) 
Adults: 600-1200 mg/d (q12h) 
 
Vancomycin* Infants and children: 60 mg/kg/d (q6h) 
Adults: 45-60 mg/kg/d (q6-12h) 
Chemoprophylaxis 
Neisseria meningitidis 
Rifampin 600 mg twice daily for two days or 
Ceftriaxone 250 mg intramuscular or 
 *Intraventricular vancomycin administration: children 10 mg/d, adults 20 mg/d 
 
Etiological	organism	
Despite	the	progress	that	has	been	made	with	vaccination,	the	most	common	causative	
organisms	of	community‐acquired	bacterial	meningitis	are	Streptococcus	pneumoniae	and	
Neisseria	meningitides.	The	tetravalent	meningococcal	vaccine	that	is	used	to	vaccinate	
adolescents	in	the	United	States,	contains	serogroups	A,	C,	W‐135	and	Y.	The	vaccine	does	not	
contain	serotype	B,	which	is	the	causative	organism	of	one	third	of	cases	of	meningococcal	disease	
in	industrialized	countries.8			The	pneumococcal	vaccines	decrease	the	incidence	of	acute	otitis	
media	and	pneumonia,	but	is	not	a	“meningitis	vaccine.”		
Predisposing	and	associated	conditions	help	predict	the	meningeal	pathogen.		In	the	patient	with	
pneumonia,	Streptococcus	pneumoniae	is	a	likely	meningeal	pathogen.	When	meningitis	is	
suspected	in	a	patient	with	a	recent	history	of	otitis,	sinusitis	or	mastoiditis,	the	etiological	
organisms	are	Streptococci	spp.	(including	S.	pneumoniae),	gram‐negative	anaerobes,	S.	aureus,	
Haemophilus	sp.,	or	Enterobacteriaceae.	The	most	common	causative	organisms	of	bacterial	
meningitis	in	the	patient	that	has	had	a	neurosurgical	procedure	are	staphylococci,	gram‐negative	
bacilli	and	anaerobes.	It	is	important	to	recognize	when	an	anaerobe	may	be	the	meningeal	
pathogen	as	that	possibility	necessitates	the	addition	of	metronidazole	to	the	empiric	regimen.	
Include	Listeria	monocytogenes	as	a	possible	meningeal	pathogen	in	the	pregnant	patient,	adults	
over	the	age	of	55,	and	in	individuals	with	impaired	cell‐mediated	immunity	due	to	chronic	illness,	
organ	transplantation,	AIDS,	malignancy	or	immunosuppressive	therapy.	This	is	important	because	
these	predisposing	factors	necessitate	the	addition	of	ampicillin	to	the	empiric	antimicrobial	
regimen.	In	general,	avoid	the	use	of	gentamicin	whenever	possible,	but	gentamicin	is	added	to	the	
empiric	antimicrobial	regimen	in	critically	ill	patients	suspected	of	having	Listeria	monocytogenes	
meningitis.		
Diagnostic	studies	
By	the	time	the	neurologist	is	consulted	by	the	Emergency	Department,	the	patient	has	had	a	
peripheral	white	blood	cell	count	and	a	CT	scan	performed.	Blood	cultures,	a	C‐reactive	protein	and	
a	serum	procalcitonin	should	be	obtained.	A	normal	C‐reactive	protein	has	a	high	negative	
predictive	value	in	the	diagnosis	of	bacterial	meningitis.5	An	elevated	serum	procalcitonin	
concentration	occurs	in	severe	bacterial	infections.	The	serum	procalcitonin	is	an	additional	helpful	
test	in	differentiating	bacterial	meningitis	from	viral	meningitis	when	the	CSF	Gram’s	stain	is	
negative.	
The	gold	standard	for	the	diagnosis	of	bacterial	meningitis	is,	of	course,	analysis	of	the	
cerebrospinal	fluid.	The	neurologist	is	critical	to	the	care	of	the	patient	with	meningitis	because	few	
physicians	other	than	neurologists	have	the	skills	to	perform	lumbar	punctures,	even	fewer	can	
manipulate	a	manometer	to	obtain	an	opening	pressure	or	have	the	knowledge	to	send	the	critical	
tests	on	spinal	fluid.	In	addition,	the	eradication	of	the	meningeal	pathogen	is	the	easy	part,	it	is	the	
recognition	and	management	of	the	neurological	complications	that	is	much	more	difficult,	but	
more	on	that	later.	
Table	3	is	the	list	of	diagnostic	tests	to	send	on	cerebrospinal	fluid	(CSF).	The	classic	CSF	
abnormalities	in	bacterial	meningitis	are	the	following:	1)	increased	opening	pressure.	It	is	always	a	
good	idea	to	put	the	additional	extension	piece	on	the	manometer,	as	opening	pressures	as	high	as	
or	higher	than	500	mm	H2O	are	not	unusual.	2)	A	pleocytosis	of	polymorphonuclear	leukocytes.	
Cerebrospinal	fluid	should	be	handled	with	care	and	examined	promptly	for	white	blood	
cells	after	it	is	obtained.	If	the	CSF	is	allowed	to	sit	around	for	hours	before	it	is	examined,	allowed	
to	get	warm	or	is	launched	through	a	hospital	tube	system,	the	white	blood	cell	count	will	be	
erroneously	low.	3)	A	glucose	concentration	of	less	than	40	mg/dL.	It	is	not	unusual	to	have	a	CSF	
glucose	concentration	in	the	single	digits.	Always	obtain	a	serum	glucose	concentration	
immediately	before	performing	a	lumbar	puncture	when	bacterial	meningitis	is	a	possibility	as	
hyperglycemia	increases	the	CSF	glucose	concentration.	A	normal	CSF:serum	ratio	is	0.6.	A	
CSF:serum	ratio	of	less	than	0.40	is	highly	predictive	of	bacterial	meningitis.	In	general,	a	
decreased	CSF	glucose	concentration	is	evidence	of	both	a	potentially	treatable	and	
potentially	fatal	central	nervous	system	(CNS)	infection	(i.e.	bacterial,	fungal,	tuberculous	or	
carcinomatous	meningitis).	4)	An	elevated	protein	concentration.	Any	process	that	increases	the	
permeability	of	the	blood	brain	barrier	increases	the	CSF	protein	concentration.	5)	Gram’s	stain	is	
positive	in	identifying	the	organism	in	60‐90%	of	cases	of	bacterial	meningitis,	but	the	probability	
of	a	positive	Gram’s	stain	is	dependent	on	the	number	of	organisms	present.	The	results	of	a	Gram’s	
stain	are	usually	available	in	four	hours.	6)	The	CSF	culture	result	is	not	only	critical	for	the	
identification	of	the	meningeal	pathogen,	but	also	for	antimicrobial	sensitivity	testing.	7)	On	the	
initial	CSF	analysis,	in	addition	to	the	presence	or	absence	of	a	pleocytosis,	the	identification	of	the	
predominant	cell	type	being	either	polymorphonuclear	leukocytes	or	lymphocytes,	the	presence	or	
absence	of	a	decreased	glucose	concentration	and	the	results	of	the	Gram’s	stain,	there	are	three	
polymerase	chain	reaction	(PCR)	assays	that	are	important	in	the	initial	diagnostic	stage.	These	are	
the	16S	rRNA	conserved	sequence	broad	based	bacterial	PCR,	the	reverse	transcriptase	(RT)	PCR	
for	enteroviruses	and	the	herpes	simplex	virus‐2	(HSV‐2)	PCR.	The	results	for	the	16S	rRNA	
bacterial	PCR	take	48	hours	or	longer	to	be	reported,	and	typically	by	the	time	this	result	is	
available	the	organism	has	been	definitively	identified	by	CSF	culture.	This	PCR	is	expected	to	be	
most	helpful	in	those	patient’s	with	a	negative	Gram’s	stain	and	culture	as	the	result	of	
pretreatment	with	antibiotics	for	their	predisposing	condition	of	pneumonia,	otitis,	sinusitis,	etc.	
Fortunately	the	RT‐PCR	for	enteroviruses	is	reported	in	four	hours.	As	enteroviruses	are	the	most	
common	cause	of	viral	meningitis,	a	positive	CSF	RT‐PCR	for	enteroviruses	is	very	helpful	in	
management	decisions.	7)	The	CSF	lactate	concentration	is	in	general	nonspecific	and	only	
recommended	in	the	diagnosis	of	bacterial	meningitis	in	the	postoperative	neurosurgical	patient.	A	
CSF	lactate	concentration	>4.0	mmol/L	is	positive.	8)	The	latex	agglutination	test	was	a	great	test	
that	is	no	longer	available.	
	
	
Table 3 Cerebrospinal fluid diagnostic studies for meningitis 
Cell count with differential 
Glucose and protein concentration 
 
Stain and culture 
 Gram’s stain and bacterial culture 
 India ink and fungal culture 
 Viral culture 
 Acid fast smear and M. tuberculosis culture 
 
Antigens/Antibodies if fungal meningitis is in the differential 
 Cryptococcal polysaccharide antigen 
 Histoplasma polysaccharide antigen 
 C. immitis complement fixation antibody 
 
Polymerase chain reaction 
 Broad range bacterial PCR (16S ribosomal DNA) 
 Specific meningeal pathogen PCR 
 Reverse transcriptase PCR for enteroviruses 
 PCR for herpes simplex virus type 1 and 2 
 PCR for West Nile virus 
 PCR for Epstein Barr virus 
 PCR for varicella zoster virus 
 PCR for M. tuberculosis 
 PCR for HIV RNA 
 
Antibodies 
 Herpes simplex virus (serum and CSF IgG to calculate antibody ratio) 
 Varicella zoster virus IgM, and IgG antibody index 
 Arthropod-borne viruses (West Nile virus IgM) 
 Borrelia burgdorferi antibody index 
 
 
 
Differential	diagnosis	
In	the	patient	with	a	clinical	presentation	of	fever,	headache	and	stiff	neck,	the	leading	disease	in	
the	differential	diagnosis	is	viral	meningitis.	Patients	with	viral	meningitis	are	awake	and	alert.	
They	are	often	sitting	on	the	examination	table	complaining	about	the	severity	of	their	headache.	
Patients	with	viral	meningitis	do	not	have	an	altered	level	of	consciousness,	seizures	or	focal	
neurological	deficits.	Patients	with	bacterial	meningitis	have	a	progressive	decrease	in	the	level	of	
consciousness	from	lethargy	to	stupor	to	obtundation	to	coma.	They	are	not	sitting	up,	but	rather,	
they	are	lying	down.	Tuberculous	meningitis	may	also	present	with	the	apoplectic	onset	of	fever	
and	headache,	and	thus	the	recommendation	that	CSF	analysis	include	a	PCR	for	Mycobacterium	
tuberculosis	and	acid	fast	smear	and	M.	tuberculosis	culture.	A	common	term	used	instead	of	PCR,	
especially	for	Mycobacterium	tuberculosis,	is	nucleic	acid	amplification	test,	the	abbreviation	of	
which	is	NAAT.	Fungal	meningitis	tends	to	have	a	more	insidious	onset	over	several	weeks	with	
headache,	fever,	cranial	nerve	palsies	and	an	altered	level	of	consciousness.		
The	list	of	medications	that	can	cause	drug‐induced	meningitis	is	ever	increasing	due	to	the	
increasing	number	of	immunomodulating	agents.	Some	of	the	better	known	culprits	are	the	
penicillins,	cephalosporins,	sulfonamides,	trimethoprim,	IVIg,	azathioprine,	cytosine	arabinoside,	
nonsteroidal	anti‐inflammatory	agents,	etc.	The	clinical	presentation	includes	fever,	headache,	stiff	
neck,	lethargy,	confusion,	seizures	and	coma.	Spinal	fluid	analysis	may	demonstrate	an	increased	
opening	pressure,	a	pleocytosis	of	polymorphonuclear	leukocytes	and	a	decreased	glucose	
concentration.	There	may	be	diffuse	enhancement	of	the	meninges	post	the	administration	of	
contrast	on	CT	or	MRI.	Cerebrospinal	fluid	Gram’s	stain	and	culture	are	negative,	and	the	symptoms	
resolve	promptly	when	the	offending	medication	is	discontinued.9		
Herpes	simplex	virus	encephalitis	is	in	the	differential	diagnosis	in	any	patient	with	fever	and	
headache.	In	the	majority	of	patients	with	herpes	simplex	virus	encephalitis,	on	fluid	attenuated	
inversion	recovery	(FLAIR)	and	diffusion‐weighted	MRI	sequences	within	48	hours	of	symptom	
onset,	there	will	be	a	hyperintensity	in	the	inferior	and	medial	temporal	lobe.	If	the	initial	CSF	PCR	
for	HSV‐1	is	negative,	and	the	suspicion	for	herpes	simplex	virus	encephalitis	is	strong,	repeat	the	
spinal	fluid	analysis.	A	false	negative	PCR	for	HSV‐1	may	occur	in	the	first	72	hours	of	symptom	
onset.	
An	infectious	intracranial	mass	lesion	will	be	readily	visualized	on	neuroimaging.	A	subarachnoid	
hemorrhage	may	also	present	like	bacterial	meningitis	with	the	sudden	onset	of	headache	and	stiff	
neck.	Neuroimaging	and	spinal	fluid	analysis	will	demonstrate	hemorrhage	prompting	CT	
angiography	for	an	intracranial	aneurysm.		
Case	#1	
A	19	year	old	freshman	at	Princeton	University	present	to	the	Emergency	Room	complaining	of	
chills,	headache	and	vomiting	for	the	last	12	hours.	He	has	recently	been	treated	with	amoxicillin	
for	an	otitis	media.	On	examination,	his	temperature	is	38.7⁰C,	he	has	photophobia	and	is	
increasingly	lethargic.	You	obtain	blood	cultures	and	treat	him	with	dexamethasone	0.15	mg/kg,	
ceftriaxone	2	gm,	vancomycin	15mg/kg,	metronidazole	500	mg	and	acyclovir	10	mg/kg.	Spinal	fluid	
analysis	demonstrates	an	opening	pressure	of	480	mm	H2O,	868	WBCs/mm3,	with	a	predominance	
of	polymorphonuclear	leukocytes,	a	glucose	concentration	of	6	mg/dL,	and	a	protein	concentration	
of	480	mg/dL.	Cerebrospinal	fluid	Gram’s	stain	demonstrates	a	gram‐negative	organism	and	
culture	grows	Fusobacterium	necrophorum.	
Comment:	Neisseria	meningitides serotype	B is	a	good	consideration	in	a	college	age	patient,	
especially	one	that	attends	Princeton	University	where	they	had	the	recent	outbreak	of	meningitis	
due	to	this	organism. The	predisposing	factor	of	otitis	media	puts	him	at	risk	for	meningitis	due	to	a	
gram‐negative	anaerobe;	thus,	the	addition	of	metronidazole	to	the	empiric	regimen	was	important.		
Management	
The	management	of	bacterial	meningitis	includes	the	eradication	of	the	meningeal	pathogen	with	
antimicrobial	therapy	as	well	as	the	prevention,	as	much	as	possible,	and	the	treatment	of	the	acute	
complications	of	this	infection.	The	acute	complications	of	bacterial	meningitis	are	increased	
intracranial	pressure,	cerebral	edema,	coma,	ischemic	and	hemorrhagic	cerebrovascular	disease,	
venous	sinus	thrombosis,	cranial	nerve	palsies	and	vestibulocochlear	involvement.	
Empiric	antimicrobial	therapy	is	modified	once	the	meningeal	pathogen	has	been	identified	and	
results	of	antimicrobial	sensitivity	testing	are	available.	Unfortunately,	it	is	both	the	multiplication	
of	the	bacterial	organisms	as	well	as	the	lysis	of	bacteria	by	bactericidal	antibiotics	with	the	release	
of	bacterial	cell	wall	components	that	initiates	the	cascade	that	leads	to	the	neurological	
complications.	The	release	of	bacterial	cell	wall	components	leads	to	the	production	of	
inflammatory	cytokines	and	chemokines	by	monocytes	and	macrophages	and	brain	astrocytes	and	
microglial	cells	(CNS‐macrophage‐equivalent	cells).	The	inflammatory	cytokines	are	the	
endogenous	host	mediators	of	inflammation	and	are	directly	responsible	for	altered	blood‐brain	
barrier	permeability,	decreased	cerebral	blood	flow,	the	purulent	exudate	in	the	subarachnoid	
space,	and	the	production	of	excitatory	amino	acids	and	reactive	oxygen	and	nitrogen	species.	The	
neurological	complications	that	occur	as	a	result	of	this	are	vasogenic,	interstitial	and	cytotoxic	
edema,	ischemic	and	hemorrhagic	stroke,	venous	sinus	thrombosis,	cranial	nerve	palsies,	seizures,	
increased	intracranial	pressure	and	coma.		
Armed	with	this	understanding,	the	obvious	intervention	to	prevent	the	pathophysiological	
consequences	and	resultant	neurological	complications	from	inflammatory	cytokines	is	to	prevent	
the	production	of	the	inflammatory	cytokines.	Thus	the	interest	in	decades	now	in	dexamethasone	
therapy.	Investigators	using	experimental	models	of	meningitis10‐12	demonstrated	dexamethasone	
inhibited	the	synthesis	of	the	inflammatory	cytokines,	reduced	meningeal	inflammation,	decreased	
cerebral	edema	and	intracranial	pressure	and	stabilized	the	blood	brain	barrier	(decreasing	
vasogenic	edema	and	the	leakage	of	serum	proteins	and	the	formation	of	the	purulent	exudate	in	
the	subarachnoid	space).	The	original	clinical	trials	on	dexamethasone	in	bacterial	meningitis	were	
done	by	Lebel	et	al.13	in	Dallas,	and	Odio	et	al.14	in	Costa	Rica.	Lebel	et	al.13	conducted	two	
consecutive	prospective	double‐blind	placebo‐controlled	trials	in	200	infants	and	children	and	
demonstrated	a	significantly	reduced	frequency	of	moderate,	severe	or	profound	bilateral	
sensorineural	hearing	loss	in	the	patients	who	received	dexamethasone.	Odio	et	al.14	conducted	a	
placebo‐controlled	double	blind	trial	of	dexamethasone	therapy	in	101	infants	and	children	and	
demonstrated	that	neurologic	sequelae	occurred	significantly	more	often	in	the	patients	who	were	
given	placebo.	These	studies	led	to	the	recommendation	by	the	American	Academy	of	Pediatrics	
that	the	use	of	dexamethasone	be	considered	in	infants	and	children	2	months	of	age	and	older	with	
proven	or	suspected	bacterial	meningitis	and	that	the	initial	does	of	dexamethasone	be	given	with	
the	initial	dose	of	antimicrobial	therapy.15		
The	initial	reluctance	to	use	dexamethasone	in	all	patients	was	that	in	the	landmark	studies	(above)	
the	majority	of	patient	were	infants	and	children	and	they	had	meningitis	due	to	Haemophilus	
influenzae	type	b.	The	efficacy	of	dexamethasone	had	yet	to	be	proven	in	adults,	or	in	meningitis	
due	to	Streptococcus	pneumoniae	or	Neisseria	meningitidis.	The	experimental	models	of	meningitis	
suggested	that	dexamethasone	should	be	efficacious	in	meningitis	due	to	either	a	gram‐positive	or	a	
gram‐negative	organism	as	each	had	a	component/s	of	their	cell	wall	that	stimulated	the	
production	of	the	inflammatory	cytokines.	
In	2002,	de	Gans	et	al.16	published	the	results	of	their	prospective,	randomized	,	double‐blind,	
multicenter	trial	of	dexamethasone	in	301	adults	with	acute	bacterial	meningitis.	Streptococcus	
pneumoniae	was	the	causative	organism	in	58	of	the	patients	in	the	dexamethasone	group	and	50	in	
the	placebo	group.	26%	of	the	patients	with	pneumococcal	meningitis	in	the	dexamethasone	group	
had	an	unfavorable	outcome	compared	with	52%	in	the	placebo	group.	14%	of	the	patients	with	
pneumococcal	meningitis	who	received	dexamethasone	died	compared	to	34%	of	those	who	
received	placebo.	After	the	initiation	of	nationwide	dexamethasone	therapy	in	adults	with	
pneumococcal	meningitis	in	the	Netherlands,	there	was	a	decline	in	the	fatality	rate	from	30%	to	
20%.7	
Both	the	Infectious	Diseases	Society	of	America	Practice	Guidelines	for	the	Management	of	Bacterial	
Meningitis5	and	the	European	Federation	of	Neurological	Societies	Guideline	on	the	Management	of	
Community‐Acquired	Bacterial	Meningitis6	recommend	the	use	of	dexamethasone	in	adults	with	
suspected	or	proven	pneumococcal	meningitis.	The	Infectious	Diseases	Society	of	America	Practice	
Guidelines	also	acknowledged	that	“some	authorities	would	initiate	dexamethasone	in	all	adults	
with	suspected	bacterial	meningitis	because	the	etiology	of	meningitis	is	not	always	ascertained	at	
initial	evaluation.5		In	fact	a	recent	study	demonstrated	a	favorable	trend	toward	reduced	rates	of	
death	and	hearing	loss	and	no	evidence	that	dexamethasone	was	harmful	in	patients	with	
meningococcal	meningitis.7		The	European	Federation	of	Neurological	Societies	Task	Force6	also	
recommends	that	dexamethasone	be	administered	to	children	with	suspected	pneumococcal	or	
Haemophilus	influenzae	type	b	meningitis.	
The	American	Academy	of	Pediatrics,	the	Infectious	Diseases	Society	of	America	and	the	European	
Federation	of	Neurological	Societies	all	agree	that	the	dose	of	dexamethasone	is	0.15	mg/kg	every	
six	hours	for	2‐4	days,	and	that	the	initial	dose	of	dexamethasone	should	be	given	either	before	or	
with	the	initial	dose	of	antimicrobial	therapy.	
Neurologists	are	often	asked	if	dexamethasone	should	be	started	four	days	or	more	after	the	
patient	has	been	treated	with	antibiotic	therapy	and	is	getting	progressively	worse.	The	answer	is	
the	evidence	supports	the	use	of	dexamethasone	at	the	initiation	of	therapy	and	for	the	first	four	
days.	After	the	inflammatory	cytokines	have	initiated	the	cascade,	therapy	should	be	directed	at	the	
specific	management	of	increased	intracranial	pressure,	seizures,	stroke,	etc.	
Cerebral	edema	and	increased	intracranial	pressure	in	bacterial	meningitis	is	managed	as	it	is	when	
it	occurs	as	a	complication	of	other	central	nervous	system	disorders	with	elevation	of	the	head	of	
the	bed,	hyperventilation	and	mannitol.	Seizures	are	often	the	result	of	cerebrovascular	
complications	and	are	treated	accordingly.	
Patients	that	develop	neurological	complications	during	the	acute	phase	of	bacterial	meningitis	are	
at	risk	for	permanent	neurological	sequelae,	including	cognitive	impairment,	hearing	loss,	seizure	
disorders,	etc.	
Spinal	epidural	abscess	
The	incidence	of	spinal	epidural	abscess	has	increased	for	two	reasons:	1)	Staphylococcus	aureus	is	
the	most	common	causative	organism,	and	infections	due	to	this	organism	have	increased,	2)	
diabetes	is	the	single	most	important	risk	factor	for	the	development	of	a	spinal	epidural	abscess.		
Neurologists	are	often	consulted	for	“weakness,”	making	the	timely	recognition	and	diagnosis	of	a	
spinal	epidural	abscess	an	entity	that	“we	own.”	We	also	care	for	these	patients	long	term,	and	as	
such	have	the	best	understanding	of	prognosis.	
A	spinal	epidural	abscess	has	a	classic	presentation	as	described	by	Heusner	in	1948.18		
 Back	pain	at	the	level	of	infection.	In	addition,	fever	may	be	present,	but	is	not	universally	
present.	
 Pain	in	a	radicular	distribution	in	the	extremities	or	an	intercostal	thoracic	dermatomal	
distribution.	
 Paresis,	loss	of	sensation	below	the	level	of	the	lesion	and	loss	of	bowel	and	bladder	control.	
 Paralysis.	
Etiological	organism	
A	spinal	epidural	abscess	develops	by	one	of	the	following	mechanisms:	1)	as	a	result	of	
hematogenous	dissemination	from	a	remote	site	of	infection		during	the	course	of	bacteremia;	2)	
from	a	contiguous	site	of	infection	(vertebral	osteomyelitis/discitis,	decubitus	ulcers,	infected	
abdominal	wounds,	soft	tissue	paravertebral	abscesses,);	3)	trauma,	and	4)	direct	inoculation	
during	spinal	instrumentation	or	epidural	analgesia.	Staphylococcus	aureus	is	the	most	common	
causative	organism	followed	by	gram‐negative	bacilli.	Empiric	antibiotic	therapy	should	include	a	
combination	of	vancomycin	and	a	third	or	fourth	generation	cephalosporin.	
Differential	diagnosis	
The	differential	diagnosis	is	defined	by	the	neurological	examination,	specifically	the	extent	and	
tempo	of	the	development	of	appendicular	weakness,	the	presence	or	absence	of	a	sensory	level,	
and	the	presence	or	absence	of	bowel	and	bladder	involvement.		Fever	and	back	pain	without	signs	
of	spinal	root	or	cord	compression	may	be	due	to	osteomyelitis	and	discitis.	The	two	most	common	
diseases	in	the	differential	diagnosis	of	spinal	epidural	abscess	are	transverse	myelitis	and	Guillian‐
Barre	syndrome.	The	clinical	presentation	of	transverse	myelitis	is	that	of	back	pain	followed	by	
lower	extremity	weakness	and	bowel	and	bladder	dysfunction.	Transverse	myelitis	affecting	the	
cervical	cord	presents	with	back	pain	and	upper	extremity	weakness.	The	findings	on	neurological	
examination	are	the	same	as	those	with	a	spinal	epidural	abscess	and	include	appendicular	
weakness,	a	well‐defined	sensory	level,	hypotonia	and	absent	or	decreased	muscle	stretch	reflexes.	
The	Guillain‐Barre	syndrome	presents	as	an	ascending	weakness	with	loss	of	the	muscle	stretch	
reflexes.	Urinary	retention	may	develop	in	the	course	of	the	illness	as	a	symptom	of	autonomic	
dysfunction,	but	is	not	a	typical	feature	of	the	acute	presentation.	
Non‐neurologists	often	want	to	image	the	entire	neuroaxis	in	a	patient	with	weakness,	but	the	
length	of	time	it	takes	to	perform	such	an	extensive	MRI	delays	getting	the	MRI.	It	is	critical	to	
localize	the	lesion	by	the	findings	on	the	neurological	examination	and	focus	the	imaging	on	the	
predicted	area	of	the	spinal	epidural	abscess	as	well	as	a	few	levels	above	and	below	that.		
Case	#2	
A	52	year	old	is	admitted	to	the	hospital	complaining	of	abdominal	pain,	slowly	progressive	
weakness	in	his	extremities	associated	with	neck	pain	and	dysphagia.	Beginning	two	weeks	prior	to	
hospitalization,	he	noted	difficulty	walking	followed	by	difficulty	with	the	strength	in	his	left	right	
upper	extremity.	At	the	time	of	admission,	he	was	catheterized	and	2	liters	of	urine	were	removed.	
He	has	had	an	indwelling	catheter	since	admission.	His	complaints	of	weakness	were	attributed	to	
his	poor	oral	intake	and	deconditioning.	He	was	evaluated	by	GI,	who	performed	
esophagogastroduodenoscopy,	which	was	normal.	ENT	also	evaluated	the	patient	and	found	no	
abnormalities	in	his	throat.	On	hospital	day	#3,	he	develops	a	fever	and	a	CBC	demonstrates	a	
neutrophilic	pleocytosis.	He	is	treated	for	an	Escherichia	coli	urinary	tract	infection.	Neurology	is	
consulted	when	he	develops	weakness	in	his	right	upper	extremity.		On	neurological	examination,	
he	has	bilateral	lower	extremity	plegia,	asymmetric	upper	extremity	hypotonic	paresis	and	a	C2	
sensory	level.	A	STAT	MRI	of	the	cervical	spine	is	obtained	(Figure	1).	He	has	a	C3	epidural	abscess	
due	to	a	paravertebral	abscess.	He	is	taken	to	the	OR	for	emergent	decompression	and	drainage	of	
the	abscess.	Gram’s	stain	of	the	purulent	material	obtained	from	C2	reveals	gram‐negative	bacilli	
and	culture	grows	E.coli.	The	neurosurgeon	notes	there	is	no	pulsation	of	the	cord	post	
decompression,	but	does	remark	about	the	presence	of	thrombosed	epidural	veins.	The	patient	
does	not	recover	the	strength	in	any	of	his	extremities.	
Comment	
The	patient’s	complaint	of	dysphagia	was	the	focus	of	evaluation	during	the	first	few	days	of	his	
hospitalization.	It	was	not	until	he	developed	weakness	under	observation	in	the	hospital	that	
neurology	was	consulted.		Despite	emergent	decompressive	surgery,	he	did	not	regain	function	in	
any	of	his	appendicular	musculature.	A	critical	piece	to	being	able	to	offer	an	opinion	on	the	
prognosis	is	what	the	neurosurgeon	sees	with	her	eyes	on	the	operative	field.	This	patient	had	
infarction	of	the	spinal	cord	due	to	septic	thrombophlebitis	and	is	not	likely	to	recover	a	significant	
degree	of	function.	
__________________________________________________________________________________________________________________	
Diagnostic	studies	
Routine	studies	for	suspected	bacterial	infection	of	the	central	nervous	system	include	CBC	with	
differential,	sed	rate,	C‐reactive	protein,	serum	procalcitonin	and	blood	cultures.	It	is	extremely	
difficult	to	obtain	an	urgent	MRI	of	the	entire	neuroaxis.	The	level	of	the	lesion	must	be	
determined	by	the	neurological	examination	to	narrow	(but	not	limit)	the	extent	of	imaging	
to	be	obtained.	
Management	
Patients	with	spinal	epidural	abscess	nearly	always	go	to	surgery	and	the	procedure	that	is	done	is	
a	decompressive	laminectomy	at	one	or	more	levels	with	drainage	of	the	abscess.	Gram’s	stain	and	
culture	of	the	purulent	material	obtained	at	the	time	of	surgery	allows	for	identification	of	the	
infecting	organism	and	modification	of	the	antimicrobial	coverage.	Antimicrobial	sensitivity	testing	
of	the	bacterial	culture	is	critical	to	ensure	that	the	organism	is	sensitive	to	the	antibiotic.	
Prognosis	
In	order	to	address	the	prognosis,	the	neurosurgeon	should	answer	the	following	questions:	1)	Did	
the	spinal	cord	pulsate	post	decompression,	and	2)	was	there	evidence	of	thrombosed	arteries	or	
veins?	If	the	neurosurgeon	does	not	address	the	likely	pathophysiology	in	their	operative	note,	they	
should	be	asked	to	do	so.	An	understanding	of	the	pathophysiology	of	the	spinal	cord	injury	
from	the	epidural	abscess	is	critical	to	predicting	the	extent	of	recovery	to	the	degree	that	
that	can	be	predicted.		
The	neurological	deficits	from	a	spinal	epidural	abscess	are	due	to	one	of	or	a	combination	of	the	
following:	1)	compression	of	the	spinal	cord,	2)	compression	of	the	arterial	blood	supply,	3)	arterial	
or	venous	thrombosis,	4)	septic	thrombophlebitis.	When	the	pathophysiology	of	the	neurological	
deficits	is	due	to	spinal	cord	compression:	“The	single	most	important	predictor	of	the	final	
neurologic	outcome	is	the	patient’s	neurologic	status	immediately	before	surgery.”19	Patients	who	
undergo	surgery	with	back	pain	or	back	pain	and	radicular	pain	are	expected	to	have	a	good	
outcome	with	no	neurological	deficits.	Those	that	undergo	surgery	with	paresis,	are	expected	to	
have	either	no	weakness	or	a	lesser	degree	of	weakness	postoperatively.	Patients	who	are	plegic	
but	operated	on	within	24	to	36	hours	of	the	development	of	paralysis	are	expected	to	regain	some	
strength	in	the	paralyzed	extremities.19	
Compression	of	the	spinal	cord	as	the	mechanism	of	injury	in	spinal	epidural	abscess	came	from	
experimental	models.	Staphylococcus	aureus	was	directly	inoculated	into	the	epidural	space	of	
rabbits	to	promote	abscess	formation.	In	this	model,	spinal	cord	compression	from	epidural	abscess	
formation	at	the	site	of	inoculation	resulted	in	paralysis.20	When	compression	is	the	mechanism	of	
injury,	improvement	from	decompressive	surgery	can	be	expected.	
When	vascular	pathology	is	the	mechanism	of	spinal	cord	injury	in	spinal	epidural	abscess,	
recovery	post	surgery	is	not	likely.	The	vascular	pathology	may	be	an	arteritis	with	spinal	cord	
ischemia,		an	arterial	or	venous	thrombosis	with	spinal	cord	ischemia	or	a	thrombophlebitis	with	
hypoxia	secondary	to	obstructed	venous	drainage	of	the	cord.21	Thrombophlebitis	of	the	
leptomeningeal	vessels	and	arterial	occlusion	have	been	visualized	intraoperatively	and	at	autopsy.	
In	these	reports,	cord	compression	was	not	the	mechanism	of	injury.22‐23It	is	also	possible	that	both	
cord	compression	and	vascular	pathology	are	the	mechanism	of	spinal	cord	injury	in	any	individual	
patient.		
This	is	such	a	devastating	disease,	and	now	that	the	incidence	of	this	disease	in	increasing,	it	is	
important	to	focus	our	efforts	on	both	prevention,	and	treatment.	Due	to	the	common	complaint	of	
back	pain,	there	is	often	a	delay	in	the	diagnosis	of	spinal	epidural	abscess.	The	presence	of	fever	
and	focal	back	pain	and	tenderness	warrants	imaging	of	the	symptomatic	level	of	the	spine.	
In	the	patient	with	a	predisposing	condition	and	thus	an	increased	risk	for	spinal	epidural	abscess,	
such	as	diabetes	or	S.	aureus	bacteremia,	a	complaint	of	back	pain	should	be	handled	with	the	same	
sense	of	urgency	as	a	complaint	of	chest	pain.	
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